CN115093999B - 一株可改善血脂紊乱的普拉梭菌及其应用 - Google Patents
一株可改善血脂紊乱的普拉梭菌及其应用 Download PDFInfo
- Publication number
- CN115093999B CN115093999B CN202210728204.1A CN202210728204A CN115093999B CN 115093999 B CN115093999 B CN 115093999B CN 202210728204 A CN202210728204 A CN 202210728204A CN 115093999 B CN115093999 B CN 115093999B
- Authority
- CN
- China
- Prior art keywords
- clostridium
- praecox
- ccfm1205
- mice
- prasugrel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000193403 Clostridium Species 0.000 title claims abstract description 78
- 210000004369 blood Anatomy 0.000 title claims abstract description 46
- 239000008280 blood Substances 0.000 title claims abstract description 46
- 150000002632 lipids Chemical class 0.000 title claims abstract description 35
- 239000005465 B01AC22 - Prasugrel Substances 0.000 claims abstract description 37
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960004197 prasugrel Drugs 0.000 claims abstract description 37
- 210000002966 serum Anatomy 0.000 claims abstract description 28
- 108010023302 HDL Cholesterol Proteins 0.000 claims abstract description 15
- 108010028554 LDL Cholesterol Proteins 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 244000005700 microbiome Species 0.000 claims abstract description 6
- 230000002222 downregulating effect Effects 0.000 claims abstract description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 12
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000273 veterinary drug Substances 0.000 claims 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 16
- 241000699670 Mus sp. Species 0.000 description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241001052560 Thallis Species 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 238000013227 male C57BL/6J mice Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 108010009004 proteose-peptone Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- -1 defoamers Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001608234 Faecalibacterium Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000604005 Homo sapiens NPC1-like intracellular cholesterol transporter 1 Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 244000061632 Prinsepia uniflora Species 0.000 description 1
- 235000008997 Prinsepia uniflora Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及一株可改善血脂紊乱的普拉梭菌及其应用,属于微生物技术领域以及医药技术领域。本发明的普拉梭菌(Faecalibacterium prausnitzii)CCFM1205具有改善血脂紊乱的作用,具体体现在:(1)显著降低血清中TC和TG的含量;(2)显著降低血液中FFA的水平;(3)显著上调HDL‑C的水平,同时下调LDL‑C的水平。因此,普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205在制备预防和/或治疗血脂紊乱的产品中,具有巨大的应用前景。
Description
技术领域
本发明涉及一株可改善血脂紊乱的普拉梭菌及其应用,属于微生物技术领域以及医药技术领域。
背景技术
血脂紊乱(Dyslipidemia)是指涉及血液任何或所有脂类以及脂蛋白异常升高水平的情况。脂质(脂溶性分子)由载脂蛋白运送,而载脂蛋白密度及结构类型决定该载脂蛋白如何对代谢产生影响。血中脂质(Lipid)主要的成分有胆固醇(cholesterol;CE)、三酸甘油酯(triglyceride;TG)与含磷脂类(phospholipid),因不溶于水,必须先与载脂蛋白AI、载脂蛋白B100结合成可溶性的脂蛋白(Lipoprotein)才可运行于血液中,输送到全身各部位。高密度脂蛋白(HDL-C)可以移除血液中多的胆固醇,而低密度脂蛋白(LDL-C)则含有大量胆固醇。。研究表明,血脂紊乱会导致动脉粥样硬化、脂肪肝、冠心病等一系列代谢性疾病。此外,模型形式的血脂紊乱还可诱发急性胰腺炎。
人类肠道微生物群的基础知识和应用知识的最新进展已经改变了当前对血脂紊乱的看法和有希望的治疗方式。人类肠道微生物群已被确定为一个复杂的生态系统,包括多种细菌物种,其数量超过1000万亿(1014数量级),为人体细胞总数的10倍以上。在漫长的进化过程中,肠道微生与人类达成了良好的互利关系,对人体的营养、代谢和免疫都扮演着重要的角色。研究表明,较之健康人群肠道菌群,血脂紊乱患者的肠道中有益菌减少而有害菌增多,且肠道中代谢物也发生了改变如短链脂肪酸的减少。
目前,治疗血脂紊乱策略主要有:调节饮食、体育锻炼、以及药物治疗。饮食锻炼一般疗法,即吃低热量、低脂食物,再结合有氧锻炼,但该种方法一般认为对普通大众并不成功,需要长期经常性地坚持;药物治疗通常是他汀类药物(Statins)、罗氏鲜(orlistat)和立控醇(Repatha),其机制主要包括抑制HDG-CoA还原酶活性,阻挡NPC1L1运送蛋白的作用,抑制PCSK9酶的活性等。但药物治疗通常会带来一定的副作用(例如腹泻和肝损伤等),且一旦停止服用容易反弹。
针对上述药物的缺点,研究人员开始尝试使用益生菌制剂治疗血脂紊乱。益生菌制剂对人体安全健康,且给药方式简便。因此,通过服用益生菌来调节肠道从而预防和治疗血脂紊乱成为一种可能的方案。
发明内容
本发明提供了一株可改善血脂紊乱的普拉梭菌(Faecalibacteriumprausnitzii),其特征在于,所述普拉梭菌(Faecalibacterium prausnitzii)CCFM1205已于2022年1月27日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:62240,保藏地址为广州市先烈中路100号大院59号楼5楼。
在一种实施方式中,所述普拉梭菌(Faecalibacterium prausnitzii)CCFM1205来源于健康成人粪便,该菌的16S rDNA序列如SEQ ID NO.1所示,该菌株在M2GSC培养基上的菌落呈圆形凸起,表面光滑,半透明状。
本发明还提供了含有所述普拉梭菌(Faecalibacterium prausnitzii)CCFM1205的产品。
在一种实施方式中,所述产品为益生菌制剂或药物。
在一种实施方式中,所述药物用于预防、缓解、改善和/或治疗血脂紊乱。
在一种实施方式中,所述益生菌制剂中除普拉梭菌CCFM1205外,还含有辅料,所述辅料包括但不限于赋形剂或食品添加剂;所述普拉梭菌CCFM1205在益生菌制剂中的含量不低于1×106CFU/mL或1×106CFU/g。
在一种实施方式中,所述药物还含有药物辅料。
在一种实施方式种,所述药物用于(a)~(c)至少一方面:
(a)改善血脂环境,降低血清中TC和TG的含量;
(b)降低血液中FFA的水平;
(c)上调HDL-C的水平,同时下调LDL-C的水平;
在一种实施方式中,所述普拉梭菌CCFM1205在药物中的含量不低于1×106CFU/mL或1×106CFU/g。
在一种实施方式中,所述改善血脂环境包括下调血液中的TC、TG、FFA、LDL-C水平,或上调HDL-C水平。
在一种实施方式中,所述药物辅料包含赋形剂以及附加剂。
在一种实施方式中,所述药物辅料包含抗黏合剂、渗透促进剂、缓冲剂、增塑剂、表面活性剂、消泡剂、增稠剂、包合剂、吸收剂、保湿剂、溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、pH值调节剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、整合剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、发泡剂、助悬剂、包衣材料、芳香剂、稀释剂、絮凝剂与反絮凝剂、助滤剂以及释放阻滞剂。
在一种实施方式中,所述附加剂包含微晶纤维素、羟丙基甲基纤维素以及精制卵磷脂。
在一种实施方式中,所述药物的剂型包含颗粒剂、胶囊剂、片剂、丸剂或口服液。
本发明还提供了含有所述普拉梭菌(Faecalibacterium prausnitzii)CCFM1205的食品、饮品、保健品、肠内营养剂、膳食补充剂、兽药或者饲料添加剂。
在一种实施方式中,所述食品包含使用含有普拉梭菌CCFM1205的发酵剂生产得到的乳制品、豆制品或果蔬制品;或所述食品包含含有所述普拉梭菌CCFM1205的固体饮料。
在一种实施方式中,所述食品、饮品、保健品、肠内营养制剂、膳食补充剂、兽药或者饲料添加剂中还含有常规辅料。
有益效果:
本发明通过动物实验证实普拉梭菌(Faecalibacterium prausnitzii)CCFM1205具有改善血脂紊乱的作用,具体体现在:
(1)血脂紊乱小鼠血清HDL-C含量由0.81±0.16mmol/L升高到了1.34±0.23mmol/L。
(2)血脂紊乱小鼠血清LDL-C含量由0.88±0.17mmol/L降低到了0.51±0.10mmol/L。
(3)血脂紊乱小鼠血清TC含量由5.38±0.56mmol/L降低到了3.51±0.76mmol/L。
(4)血脂紊乱小鼠血清TG含量由1.85±0.28mmol/L降低到了1.02±0.24mmol/L。
(5)血脂紊乱小鼠血清FFA含量由2.02±0.22mmol/L降低到了1.09±0.33mmol/L。
因此,普拉梭菌(Faecalibacterium prausnitzii)CCFM1205在制备预防和/或治疗血脂紊乱产品(如食品、药品或保健品等)中,具有巨大的应用前景。
生物材料保藏
普拉梭菌(Faecalibacterium prausnitzii)CCFM1205,分类学命名为Faecalibacterium prausnitzii,已于2022年1月27日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:62240,保藏地址为广州市先烈中路100号大院59号楼5楼。
附图说明
图1:不同组别实验小鼠血清中HDL-C的含量。
图2:不同组别实验小鼠血清中LDL-C的含量。
图3:不同组别实验小鼠血清中TC的含量。
图4:不同组别实验小鼠血清中TG的含量。
图5:不同组别实验小鼠血清中FFA的含量。
具体实施方式
下面结合具体实施例对本发明进行进一步的阐述。
下述实施例中涉及的脱脂乳购自光明乳业股份有限公司,葡萄糖与酵母浸膏购自国药集团化学试剂有限公司,酪蛋白胨购自上海创赛公司,TC、FFA、TG、HDL-C和LDL-C试剂盒购自美国Beckman coulter公司。
模式菌株普拉梭菌(Faecalibacterium prausnitzii)A2-165获取自德国微生物菌种保藏中心(DSMZ),保藏编号为DSMZ 17677。
下述实施例中涉及的培养基如下:
M2GSC固体培养基(g/L):酵母粉5g/L、酪蛋白胨10g/L、葡萄糖5g/L、纤维二糖2g/L、果糖2g/L、碳酸氢钠4g/L、氯化钠0.9g/L、磷酸二氢钾0.45g/L、磷酸氢二钾0.45g/L、硫酸镁0.09g/L、氯化钙0.09g/L、琼脂15g/L、半胱氨酸0.5g/L、刃天青1.0mg/L,澄清瘤胃液10mL/L。
M2GSC液体培养基(g/L):酵母粉5g/L、酪蛋白胨10g/L、葡萄糖5g/L、纤维二糖2g/L、果糖2g/L、碳酸氢钠4g/L、氯化钠0.9g/L、磷酸二氢钾0.45g/L、磷酸氢二钾0.45g/L、硫酸镁0.09g/L、氯化钙0.09g/L、半胱氨酸0.5g/L、刃天青1.0mg/L,澄清瘤胃液10mL/L。
实施例1:普拉梭菌的筛选及菌种鉴定
(1)筛选
以来源于江苏无锡地区的健康人体粪便为样本,在样品采集后的一小时内立即将其转移至厌氧工作站内进行处理。取一勺粪便样品,加入到5mL PBS(加入0.05%半胱氨酸)中,混匀进行梯度稀释,选择10-5~10-7的梯度稀释液涂布在上述M2GSC固体培养基上,于37℃培养48h,挑取典型菌落至两份M2GSC固体培养基中,一份置于厌氧工作站培养(命名为A板),另一份置于厌氧工作站外暴露30min再拿回至厌氧工作站培养(命名为B板),于培养温度均为37℃,培养48h后挑取B板中不长的菌落至M2GSC固体培养基上划线纯化,同时进行特异性引物检测。纯化完成后,挑取单菌落转接至M2GSC液体培养基中于37℃培养,于厌氧工作站内抽滤收集菌泥,30%甘油保藏,得到菌株菌株CCFM1205。
(2)鉴定
挑取CCFM1205单菌落进行菌落PCR,以对其16s rDNA进行扩增和测序(由金唯智公司进行)。CCFM1205的16s rDNA的序列为SEQ ID NO.1,将该序列在NCBI中进行核酸序列比对,结果显示菌株均为普拉梭菌,命名为普拉梭菌(Faecalibacterium prausnitzii)CCFM1205。
实施例2:普拉梭菌的培养
将普拉梭菌(Faecalibacterium prausnitzii)CCFM1205接入M2GSC固体培养基中于37℃培养48h后,观察其菌落,发现其菌落凸面,半透明,边缘完整,湿润。
将普拉梭菌(Faecalibacterium prausnitzii)CCFM1205按2%接种量接入M2GSC液体培养基中,并于37℃厌氧培养24h后,转入新鲜的M2GSC液体培养基中,同样条件培养24h,在厌氧工作站内抽滤获得菌泥,继而用0.1M PBS(pH 7.2,含0.05%半胱氨酸)洗涤重悬后得到菌浓为1×109CFU/mL悬液,使用密封性良好的冻干瓶加塞保存菌悬液,当天使用。
实施例3:普拉梭菌对血脂紊乱小鼠血清HDL-C的影响
将32只SPF级雄性C57BL/6J小鼠(8周龄,18-22g)随机分为4组,每组8只,分别为空白组、模型组、A2-165组和CCFM1205组。小鼠饲养在江南大学实验动物中心,恒定温度21-26℃,湿度40-70%,噪声小于等于60dB,动物照度15-20LX(所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准)。
实验共13周:小鼠先适应性喂养7天,从第8天开始,开始使用高脂饲料喂养模型组小鼠和干预组小鼠,空白组仍然使用普通饲料。此外,干预组小鼠(CCFM1203组和A2-165组)从第8天开始每天分别灌胃0.2mL菌液浓度为1×109/mL的普拉梭菌CCFM1205和普拉梭菌模式菌株A2-165菌液,空白组和模型组则灌胃等量体积的PBS溶液。
实验结束后,取血并处死小鼠,血液经室温放置1h后,于4℃下3500r/min离心10min,收集血清,通过试剂盒测定血清中HDL-C含量,结果见图1。
如图1所示,相较于空白组的1.65±0.27mmol/L,模型组小鼠HDL-C含量显著下降至0.81±0.16mmol/L(P<0.05)。小鼠在喂食本发明中的菌株普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205后,HDL-C含量较之模型组显著提高了64.23%(P<0.05),模式菌株A2-165的提高量为35.94%(P<0.05)。以上实验表明,普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205可显著提高血脂紊乱小鼠的HDL-C含量,且效果显著优于普拉梭菌(Faecalibacterium prausnitzii)模式菌株A2-165。
实施例4:普拉梭菌对血脂紊乱小鼠血清LDL-C的影响
将32只SPF级雄性C57BL/6J小鼠(8周龄,18-22g)随机分为4组,每组8只,分别为空白组、模型组、A2-165组和CCFM1205组。小鼠饲养在江南大学实验动物中心,恒定温度21-26℃,湿度40-70%,噪声小于等于60dB,动物照度15-20LX(所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准)。
实验共13周:小鼠先适应性喂养7天,从第8天开始,开始使用高脂饲料喂养模型组小鼠和干预组小鼠,空白组仍然使用普通饲料。此外,干预组小鼠(CCFM1203组和A2-165组)从第8天开始每天分别灌胃0.2mL普拉梭菌CCFM1205和普拉梭菌模式菌株A2-165菌液(1×109/mL),空白组和模型组则灌胃等量体积的PBS溶液。
实验结束后,取血并处死小鼠,血液经室温放置1h后,于4℃下3500r/min离心10min,收集血清,通过试剂盒测定血清中LDL-C含量,结果见图2。
如图2所示,相较于空白组的0.28±0.04mmol/L,模型组小鼠LDL-C含量显著上升至0.88±0.17mmol/L(P<0.05)。小鼠在喂食本发明中的菌株普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205后,LDL-C含量较之模型组显著降低了41.94%(P<0.05),模式菌株A2-165组降低了24.24%(P<0.05)。以上实验表明,普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205可显著降低血脂紊乱小鼠的LDL-C含量,且效果显著优于普拉梭菌(Faecalibacterium prausnitzii)模式菌株A2-165。
实施例5:普拉梭菌对血脂紊乱小鼠血清TC的影响
将32只SPF级雄性C57BL/6J小鼠(8周龄,18-22g)随机分为4组,每组8只,分别为空白组、模型组、A2-165组和CCFM1205组。小鼠饲养在江南大学实验动物中心,恒定温度21-26℃,湿度40-70%,噪声小于等于60dB,动物照度15-20LX(所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准)。
实验共13周:小鼠先适应性喂养7天,从第8天开始,开始使用高脂饲料喂养模型组小鼠和干预组小鼠,空白组仍然使用普通饲料。此外,干预组小鼠(CCFM1203组和A2-165组)从第8天开始每天分别灌胃0.2mL普拉梭菌CCFM1205和普拉梭菌模式菌株A2-165菌液(1×109/mL),空白组和模型组则灌胃等量体积的PBS溶液。
实验结束后,取血并处死小鼠,血液经室温放置1h后,于4℃下3500r/min离心10min,收集血清,通过试剂盒测定血清中TC含量,结果见图3。
如图3所示,相较于空白组的1.97±0.40mmol/L,模型组小鼠TC含量显著上升至5.38±0.56mmol/L(P<0.05)。小鼠在喂食本发明中的菌株普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205后,TC含量较之模型组显著下降了34.73%(P<0.05),A2-165组降低了21.93%;以上实验表明,普拉梭菌(Faecalibacterium prausnitzii)CCFM1205可显著降低血脂紊乱小鼠的TC含量,且效果显著优于普拉梭菌模式菌株A2-165。
实施例6:普拉梭菌对血脂紊乱小鼠血清TG的影响
具体步骤如下:
将32只SPF级雄性C57BL/6J小鼠(8周龄,18-22g)随机分为4组,每组8只,分别为空白组、模型组、A2-165组和CCFM1205组。小鼠饲养在江南大学实验动物中心,恒定温度21-26℃,湿度40-70%,噪声小于等于60dB,动物照度15-20LX(所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准)。
实验共13周:小鼠先适应性喂养7天,从第8天开始,开始使用高脂饲料喂养模型组小鼠和干预组小鼠,空白组仍然使用普通饲料。此外,干预组小鼠(CCFM1203组和A2-165组)从第8天开始每天分别灌胃0.2mL普拉梭菌CCFM1205和普拉梭菌模式菌株A2-165菌液(1×109/mL),空白组和模型组则灌胃等量体积的PBS溶液。
实验结束后,取血并处死小鼠,血液经室温放置1h后,于4℃下3500r/min离心10min,收集血清,通过试剂盒测定血清中TG含量,结果见图4。
如图4所示,相较于空白组的0.84±0.13mmol/L,模型组小鼠TG含量显著上升至1.85±0.28mmol/L(P<0.01)。小鼠在喂食本发明中的菌株普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205后,TG含量较之模型组显著下降了44.87%,接近正常组小鼠TG水平,而A2-165组相对于模型组仅降低了27.90%。以上实验表明,普拉梭菌(Faecalibacterium prausnitzii)CCFM1205可显著降低血脂紊乱小鼠的TG含量,且效果显著优于普拉梭菌(Faecalibacterium prausnitzii)模式菌株A2-165。
实施例7:普拉梭菌对血脂紊乱小鼠血清FFA的影响
将32只SPF级雄性C57BL/6J小鼠(8周龄,18-22g)随机分为4组,每组8只,分别为空白组、模型组、A2-165组和CCFM1205组。小鼠饲养在江南大学实验动物中心,恒定温度21-26℃,湿度40-70%,噪声小于等于60dB,动物照度15-20LX(所有动物实验程序皆由江南大学动物福利与伦理管理委员会进行审查并批准)。
实验共13周:小鼠先适应性喂养7天,从第8天开始,开始使用高脂饲料喂养模型组小鼠和干预组小鼠,空白组仍然使用普通饲料。此外,干预组小鼠(CCFM1203组和A2-165组)从第8天开始每天分别灌胃0.2mL普拉梭菌CCFM1205和普拉梭菌模式菌株A2-165菌液(1×109/mL),空白组和模型组则灌胃等量体积的PBS溶液。
实验结束后,取血并处死小鼠,血液经室温放置1h后,于4℃下3500r/min离心10min,收集血清,通过试剂盒测定血清中FFA含量,结果见图5。
如图5所示,相较于空白组的0.97±0.20mmol/L,模型组小鼠FFA含量显著上升至2.02±0.22mmol/L(P<0.05)。小鼠在喂食本发明中的菌株普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205后,FFA含量较之模型组显著下降了45.94%(P<0.05),较之正常组无显著差异,而A2-165组仅降低了28.93%。以上实验表明,普拉梭菌(Faecalibacteriumprausnitzii)CCFM1205可显著降低血脂紊乱小鼠的FFA含量,且效果显著优于普拉梭菌(Faecalibacterium prausnitzii)模式菌株A2-165。
实施例8:含有普拉梭菌CCFM1205的固体饮料的制备
将普拉梭菌CCFM1205按照占培养基总质量3%的接种量接种到培养基中,于37℃下培养18h,得到培养液;将培养液离心,得到菌体;将菌体用pH为7.2的磷酸盐缓冲液清洗3次后用海藻糖浓度为100g/L的海藻糖冻干保护剂重悬(冻干保护剂和菌体的质量比为2:1),得到菌浓为5×108CFU/mL的重悬液;将重悬液采用真空冷冻法进行冻干,得到普拉梭菌CCFM1205菌粉。
将含有109CFU/g的普拉梭菌CCFM1205菌粉同麦芽糊精以2:1进行混合,CCFM1205菌粉和麦芽糊精总质量为1克,得到富含普拉梭菌CCFM1205的固体饮料。
取10克(相当于共灌1010CFU)上述含有普拉梭菌CCFM1205的固体饮料,用生理盐水复溶,定容到20毫升,每只小鼠每天灌胃200微升,连续12周,可有效改善血脂紊乱症状、提高HDL-C的含量、同时降低TC、TG、FFA和LDL-C的含量,从而达到改善血脂紊乱的效果。
实施例9:含有普拉梭菌CCFM1205的牛乳的制备
具体步骤如下:
将普拉梭菌CCFM1205按照占培养基总质量3%的接种量接种到培养基中,于37℃下培养18h,得到培养液;将培养液离心,得到菌体;将菌体用pH为7.2的磷酸盐缓冲液清洗3次后用海藻糖浓度为100g/L的海藻糖冻干保护剂重悬至菌浓度达到1×1010CFU/mL,得到菌悬液;将悬浮液于37℃下放置60min进行预培养后采用冻干法冻干,得到普拉梭菌CCFM1205发酵剂;其中,所述培养基包含占培养基总质量87.7%的水、10%的酶水解脱脂乳、0.5%的葡萄糖、1.5%的胰蛋白胨以及0.3%的酵母浸膏溶解;所述培养基的pH为6.8;
将脱脂乳在95℃热杀菌20min,然后冷却至4℃,加入普拉梭菌CCFM1205发酵剂,使乳脱脂奶中普拉梭菌CCFM1205活菌浓度达到1×109CFU/mL,在4℃下冷藏保存,得到含有普拉梭菌FJNJZ1Y10活菌的牛乳。
取200微升含有普拉梭菌FJNJZ1Y10活菌的牛乳,对小鼠进行灌胃连续12周,可有效改善血脂紊乱症状,提高HDL-C的含量、同时降低TC、TG、FFA和LDL-C的含量,从而达到改善血脂紊乱的效果。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
SEQUENCE LISTING
<110> 江南大学
<120> 一株可改善血脂紊乱的普拉梭菌及其应用
<130> BAA2111280A
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1390
<212> DNA
<213> Faecalibacterium prausnitzii
<400> 1
ctaccatgca agtcgaacga gagagaagga gcttgcttct tcgatcgagt ggcgaacggg 60
tgagtaacgc gtgaggaacc tgcctcaaag agggggacaa cagttggaaa cgactgctaa 120
taccgcataa gcccacgggt cggcatcgac cagagggaaa aggagcaatc cgctttgaga 180
tggcctcgcg tccgattagc tagttggtga ggtaatggcc caccaaggcg acgatcggta 240
gccggactga gaggttgaac ggccacattg ggactgagac acggcccaga ctcctacggg 300
aggcagcagt ggggaatatt gcacaatggg ggaaaccctg atgcagcgac gccgcgtgga 360
ggaagaaggt cttcggattg taaactcctg ttgttgagga agataatgac ggtactcaac 420
aaggaagtga cggctaacta cgtgccagca gccgcggtaa aacgtaggtc acaagcgttg 480
tccggaatta ctgggtgtaa agggagcgca ggcgggaaga caagttggaa gtgaaatcca 540
tgggctcaac ccatgaactg ctttcaaaac tgtttttctt gagtagtgca gaggtaggcg 600
gaattcccgg tgtagcggtg gaatgcgtag atatcgggag gaacaccagt ggcgaaggcg 660
gcctactggg caccaactga cgctgaggct cgaaagtgtg ggtagcaaac aggattagat 720
accctggtag tccacaccgt aaacgatgat tactaggtgt tggaggattg accccttcag 780
tgccgcagtt aacacaataa gtaatccacc tggggagtac gaccgcaagg ttgaaactca 840
aaggaattga cgggggcccg cacaagcagt ggagtatgtg gtttaattcg acgcaacgcg 900
aagaacctta ccaagtcttg acatcctgcg acggacatag aaataggatt ttccttcggg 960
acgcagagac aggtggtgca tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt 1020
cccgcaacga gcgcaaccct tatggtcagt tactacgcaa gaggactctg gccagactgc 1080
cgttgacaaa acggaggaag gtggggatga cgtcaaatca tcatgccctt tatgacttgg 1140
gctacacacg tactacaatg gcgttaaaca aagagaagca agaccgcgag gtggagcaaa 1200
actcagaaac aacgtcccag ttcggactgc aggctgcaac tcgcctgcac gaagtcggaa 1260
ttgctagtaa tcgtggatca gcatgccacg gtgaatacgt tcccgggcct tgtacacacc 1320
gcccgtcaca ccatgagagc cggggggacc cgaagtcggt agtctaaccg caaggaggac 1380
gccgccgaag 1390
Claims (8)
1.一株普拉梭菌(Faecalibacterium prausnitzii),其特征在于,所述普拉梭菌CCFM1205已于2022年1月27日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:62240。
2.含有权利要求1所述普拉梭菌(Faecalibacterium prausnitzii)CCFM1205的产品;所述产品为微生物制剂或药物。
3.根据权利要求2所述的产品,其特征在于,所述普拉梭菌的活菌数为不低于1×106CFU/mL或1×106 CFU/g。
4.权利要求1所述的普拉梭菌在制备用于预防、缓解、改善和/或治疗血脂紊乱的药物中的应用。
5.根据权利要求4所述的应用,其特征在于,所述药物具有(a)~(c)至少一种作用:
(a)改善血脂环境,降低血清中TC和TG的含量;
(b)降低血液中FFA的水平;
(c)上调HDL-C的水平,下调LDL-C的水平。
6.根据权利要求4或5所述的应用,其特征在于,所述药物还含有药物辅料。
7.根据权利要求4或5所述的应用,其特征在于,所述药物的剂型为颗粒剂、胶囊剂、片剂、丸剂或口服液。
8.含有权利要求1所述普拉梭菌CCFM1205的兽药。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210728204.1A CN115093999B (zh) | 2022-06-24 | 2022-06-24 | 一株可改善血脂紊乱的普拉梭菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210728204.1A CN115093999B (zh) | 2022-06-24 | 2022-06-24 | 一株可改善血脂紊乱的普拉梭菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115093999A CN115093999A (zh) | 2022-09-23 |
CN115093999B true CN115093999B (zh) | 2023-10-27 |
Family
ID=83293571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210728204.1A Active CN115093999B (zh) | 2022-06-24 | 2022-06-24 | 一株可改善血脂紊乱的普拉梭菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115093999B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115074277B (zh) * | 2022-06-24 | 2023-09-26 | 无锡特殊食品与营养健康研究院有限公司 | 一株可缓解肥胖的普拉梭菌及其应用 |
CN115737687A (zh) * | 2022-10-16 | 2023-03-07 | 新疆医科大学第一附属医院 | 普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019046646A1 (en) * | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
CN111107860A (zh) * | 2017-06-16 | 2020-05-05 | 表飞鸣制药株式会社 | 脂肪相关疾病和/或炎症的预防或治疗剂 |
CN112402459A (zh) * | 2020-10-27 | 2021-02-26 | 江南大学 | 普拉梭菌缓解过敏性哮喘和鼻炎Th2反应中的应用 |
-
2022
- 2022-06-24 CN CN202210728204.1A patent/CN115093999B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111107860A (zh) * | 2017-06-16 | 2020-05-05 | 表飞鸣制药株式会社 | 脂肪相关疾病和/或炎症的预防或治疗剂 |
WO2019046646A1 (en) * | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
CN112402459A (zh) * | 2020-10-27 | 2021-02-26 | 江南大学 | 普拉梭菌缓解过敏性哮喘和鼻炎Th2反应中的应用 |
Non-Patent Citations (4)
Title |
---|
Dengfeng Xu等.The Prebiotic Effects of Oats on Blood Lipids, Gut Microbiota, and Short-Chain Fatty Acids in Mildly Hypercholesterolemic Subjects Compared With Rice: A Randomized, Controlled Trial.《Frontiers in Immunology》.2021,参见全文. * |
吴桐等.肥胖人群肠道菌群特征分析及机器学习模型.《微生物学通报》.2020,参见全文. * |
杨浩等.新疆维吾尔族2型糖尿病人群肠道中Faecalibacterium prausnitzii的定量研究.《中国微生态学杂志》.2017,参见全文. * |
胡日查等.普拉梭菌的生物学特性及其与宿主的相互作用.《中国食品学报》.2020,参见全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN115093999A (zh) | 2022-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115093999B (zh) | 一株可改善血脂紊乱的普拉梭菌及其应用 | |
CN113293113B (zh) | 一株长双歧杆菌mi-186及其应用 | |
CN110643542B (zh) | 一株可缓解变应性哮喘Th2反应的罗伊氏乳杆菌及其应用 | |
CN115927045B (zh) | 具有降胆固醇、缓解由高脂血症引起肝损伤功能的唾液乳杆菌069及其应用 | |
CN106883995A (zh) | 乳酸片球菌jqii-5菌株及其用途 | |
CN115505551B (zh) | 瑞士乳杆菌及其在预防或治疗肾炎中的应用 | |
CN116024130A (zh) | 一株降血尿酸发酵乳杆菌a21215及其应用 | |
CN116396890B (zh) | 用于防治结肠癌的植物乳杆菌zjuids15及其应用 | |
CN111979161A (zh) | 一株可降低血管平滑肌细胞内活性氧水平的长双歧杆菌 | |
CN112899190A (zh) | 对痛风具有预防和/或改善功能的副干酪乳杆菌lpc48及其用途 | |
CN114107121A (zh) | 一种凝结芽孢杆菌及其在酒精性肝病的治疗中的应用 | |
CN113797232B (zh) | 具有缓解胰岛素抵抗功能的组合物及其应用 | |
CN114657084B (zh) | 一种缓解溃疡性结肠炎的长双歧杆菌及其应用 | |
CN113355252A (zh) | 一种副干酪乳杆菌及其应用 | |
US10307445B2 (en) | Bacterial strains having an outstanding ability to produce menaquinone | |
CN116970539B (zh) | 一种鼠联合乳杆菌、其组合物及用途 | |
CN111035658A (zh) | 戊糖片球菌的用途 | |
CN115074276B (zh) | 一株能够缓解非酒精性脂肪肝的普拉梭菌及其应用 | |
CN112029676B (zh) | 一种有利于提高免疫力的益生菌组合及其应用 | |
CN117645941A (zh) | 一种通过同时降解尿酸和嘌呤核苷缓解高尿酸血症的发酵粘液乳杆菌及其应用 | |
CN110616167B (zh) | 能够缓解特应性皮炎的双歧杆菌及其应用 | |
CN114686405B (zh) | 一株具有减少脂肪和缓解高血糖,调节肠道免疫力的两歧双歧杆菌及其应用 | |
CN116004472A (zh) | 一株缓解肥胖的丁酸梭菌及其应用 | |
CN115992059A (zh) | 一株产阿魏酸酯酶的约氏乳杆菌及其缓解溃疡性结肠炎的用途 | |
CN115074277B (zh) | 一株可缓解肥胖的普拉梭菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |